Xtant Medical - XTNT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.60
  • Forecasted Upside: 91.18%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.84
+0 (0.00%)

This chart shows the closing price for XTNT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Xtant Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XTNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XTNT

Analyst Price Target is $1.60
▲ +91.18% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Xtant Medical in the last 3 months. The average price target is $1.60, with a high forecast of $2.00 and a low forecast of $1.20. The average price target represents a 91.18% upside from the last price of $0.84.

This chart shows the closing price for XTNT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Xtant Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/5/2023BTIG ResearchInitiated CoverageBuy$2.00
7/11/2023Craig HallumBoost Target$1.00 ➝ $1.20
4/26/2023Craig HallumInitiated CoverageBuy
5/17/2019Maxim GroupDowngradeBuy ➝ Hold
(Data available from 4/20/2019 forward)

News Sentiment Rating

-0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Xtant Medical logo
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Read More

Today's Range

Now: $0.84
Low: $0.80
High: $0.90

50 Day Range

MA: N/A

52 Week Range

Now: $0.84
Low: $0.60
High: $1.45

Volume

123,193 shs

Average Volume

146,567 shs

Market Capitalization

$108.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Xtant Medical?

The following Wall Street sell-side analysts have issued reports on Xtant Medical in the last twelve months: BTIG Research, Craig Hallum, and TheStreet.
View the latest analyst ratings for XTNT.

What is the current price target for Xtant Medical?

2 Wall Street analysts have set twelve-month price targets for Xtant Medical in the last year. Their average twelve-month price target is $1.60, suggesting a possible upside of 91.2%. BTIG Research has the highest price target set, predicting XTNT will reach $2.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $1.20 for Xtant Medical in the next year.
View the latest price targets for XTNT.

What is the current consensus analyst rating for Xtant Medical?

Xtant Medical currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XTNT will outperform the market and that investors should add to their positions of Xtant Medical.
View the latest ratings for XTNT.

What other companies compete with Xtant Medical?

How do I contact Xtant Medical's investor relations team?

Xtant Medical's physical mailing address is 664 Cruiser Ln, BELGRADE, MT 59714-9719, United States. The medical device company's listed phone number is (406) 388-0480 and its investor relations email address is [email protected]. The official website for Xtant Medical is xtantmedical.com. Learn More about contacing Xtant Medical investor relations.